Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Field Trials

26 Nov 2008 07:00

RNS Number : 9440I
Plant Health Care PLC
26 November 2008
 



26 November 2008

Plant Health Care plc ("Plant Health Care" or the "Company")

Results of the ASA Sponsored N-Hibit Seed Treatment Program

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries and  the American Soybean Association ("ASA") are pleased to announce that the "N-Hibit® Seed Treatment Satisfaction Guarantee" program during the 2008 growing season was an unqualified success.

The results of the N-Hibit Seed Treatment program over 17 replicated trial sites, ranging from Ohio to Nebraska, produced N-Hibit-treated yields averaging 62.0 bushels/acre compared to the untreated control average of 58.6 bushels/acre. This represents a yield increase of 3.4 bushels/acre or 5.8 per cent. As a consequence, less than 3 per cent. of the acreage treated with N-Hibit resulted in requests for refunds under the Seed Treatment Satisfaction Guarantee Program. The combined effect of nematode reduction and enhanced plant growth are the primary reasons for these excellent results.

ASA President John Hoffman, a soybean producer from WaterlooIowa, commented:

"ASA partnered with PHC on the project because part of ASA's mission is to help identify new ways for ASA members to maximize soybean yield and profitability. N-Hibit's ability to reduce SCN damage and boost overall plant health is consistent with that mission, so ASA worked with PHC to make our members aware of the Satisfaction Guarantee program."

Rick Rice, Plant Health Care Director, Sales & MarketingUSA Agricultural Division stated:

"We wanted growers to share our confidence, and the Satisfaction Guarantee program assured them of a full refund of the purchase price paid for N-Hibit if they weren't fully satisfied with its performance on treated acreage. With a better than 97 percent success rate and the relationships we have developed with all the farmers involved in the program, we couldn't be more pleased." 

The active ingredient in N-Hibit is harpin protein, which stimulates the same plant growth response that occurs when a plant experiences stress. The induced response results in a healthier plant and a reduction in the number of nematodes that host on the roots. Harpin proteins do not enter the plant. They bind with the plant's external harpin protein receptors, which are present on both seed and foliage. After the proteins initiate the plant's natural self defense and growth systems, they harmlessly disintegrate. For more information about PHC, please visit www.planthealthcare.com.

  For more information contact: 

John Hoffman, ASA President +001 (319) 233 9480

John Brady, Plant Health Care plc CEO +001 603 525 3702

Evolution Securities Limited +44 (0)20 7071 4300

Tim Worlledge / Tim Redfern

Tavistock Communications Limited +44 (0)20 7920 3150

Jeremy Carey / Matt Ridsdale

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAAFSAFXPFAE
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.